Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00570 TRAD CHI MED
RTNominal down4.300 -0.020 (-0.463%)
Others

23/04/2018 10:33

Trad Chi Med's drug clinical trial shows positive results

[ET Net News Agency, 23 April 2018] China Traditional Chinese Medicine (00570) said,
sponsored by the Chinese Journal of practical Pediatrics and the Chinese traditional
Medicine Association, "inheriting the Classics," the randomized, double-blind, positive
and placebo-controlled, multi-centered clinical trial (RCT) results of the efficacy and
safety of Yupingfeng Granules in the treatment of recurrent respiratory tract infections
in children were announced in Beijing.
The results showed that the efficacy of Yuping Feng Granules in the treatment of
recurrent respiratory tract infection in children was non-inferior to the positive control
group, and superior to the placebo group, and the risk of having respiratory tract
infection was significantly reduced by Yuping Feng Granules compared with placebo. In the
course of clinical study, there was no adverse events occurred during the study and the
clinical safety was high.
This study is the first clinical study on the treatment of recurrent respiratory tract
infection in pediatrics in accordance with the GCP standard. It will promote the
evidence-based development of Chinese medicine and set up a model of evidence-based
research in the field of traditional Chinese medicine in China. The results of RCT further
clarify the clinical value of Yuping Feng Granules and provide reliable and high quality
treatment plan for doctors. It is of positive significance to expand the sales of
Yupingfeng Granules in hospital. (HL)

Remark: Real time quote last updated: 26/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.